Short answer
Sana Biotechnology, Inc. (SANA) filed an 8-K current report with the SEC on March 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events). Q4 and full-year 2025 financial results announced March 3, 2026.
Sana Biotechnology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full-year 2025 financial results announced March 3, 2026
- Actual figures in Exhibit 99.1 press release: key metrics not disclosed in this filing item
Item 8.01 · Other Events
- ATM offering expanded: new S-3 filed for up to $150M in common stock sales via TD Cowen as agent
- Prior ATM (May 2025) sold ~11.3M shares for ~$45.8M net proceeds; ~$71.6M of prior capacity unused but now superseded
- TD Cowen compensation capped at 3.0% of gross proceeds; company retains full discretion on timing, size, and minimum price
- Significant dilution risk: $150M at current prices represents material share count increase for existing holders
- Company can suspend or terminate sales at any time: actual draw may be well below $150M ceiling depending on cash needs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Sana Biotechnology, Inc. 8-K filings
Get the next SANA 8-K as it lands
Follow SANA for push alerts, or ask the research agent what this filing means.